92 results on '"Natalucci F"'
Search Results
2. OP0165 DIFFICULT TO TREAT RHEUMATOID ARTHRITIS INCIDENCE AND RISK FACTORS IN THE EARLY ARTHRITIS UCLOUVAIN BRUSSELS COHORT
3. POS1131 EVOLUTIONARY TRAJECTORY OF UNDIFFERENTIATED CONNECTIVE TISSUE DISEASE: IMPACT OF THE 2019 EULAR/ACR CLASSIFICATION CRITERIA FOR SYSTEMIC LUPUS ERYTHEMATOSUS
4. AB1011 COMPREHENSIVE DISEASE CONTROL IN SYSTEMIC LUPUS ERYTHEMATOSUS: WHEN REMISSION GOES HAND IN HAND WITH THE CONTROL OF CHRONIC DAMAGE
5. AB0611 PREDICTORS OF RA DEVELOPMENT IN PATIENTS WITH ACPA POSITIVE UNDIFFERENTIATED ARTHRITIS: A 2 TO 20 YEARS FOLLOW-UP STUDY OF THE ARTHRITIS UCLOUVAIN BRUSSELS COHORT
6. POS0687 FEASIBILITY, SAFETY, AND APPLICATION FOR CLINICAL INDICATION AND RESEARCH PURPOSES OF SYNOVIAL TISSUE ANALYSIS IN RHEUMATOID ARTHRITIS
7. Inclusion of Fibrinoid Necrosis increases the accuracy of synovial tissue assessment in predicting response to methotrexate: analysis of the UCLouvain Brussels ERA Cohort
8. L’hétérogénéité dans la localisation articulaire soutient l’importance des facteurs locaux dans la synovite précoce de la PR : analyse de la cohorte PR UCLouvain Bruxelles
9. La résolution du nombre d’articulations gonflées est un objectif clinique important au début de la polyarthrite rhumatoïde : analyse de la cohorte ERA de l’UCLouvain Bruxelles et comparaison avec l’indice composite de rémission
10. CD68 et la nécrose fibrinoïde sont des biomarqueurs synoviaux de la sévérité de la polyarthrite rhumatoïde précoce et sont associés à une meilleure réponse au méthotrexate : analyse de la cohorte PR-précoce de l’UCLouvain Bruxelles
11. Immune checkpoint inhibitors and pre-existing antinuclear antibodies: the rheumatologist point of view
12. AB0672 DETECTION OF MACROPHAGE MIGRATION INHIBITORY FACTOR IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS COMPLAINING PAINFUL DISTURBANCES: A SINGLE CENTER STUDY
13. POS0314 CAN METHOTREXATE INFLUENCE SEXUAL DYSFUNCTION IN MALE PATIENTS: ANALYSIS OF THE IIEF5 QUESTIONNAIRE AND HORMONAL STATUS
14. AB0590 CROSS-SECTIONAL ASSESSMENT OF THE QUALITY OF LIFE IN SLE PATIENTS: ROLE OF DISEASE ACTIVITY, CHRONIC DAMAGE, FIBROMYALGIA SYNDROME AND MOOD DISORDERS
15. S13.1 Developing systemic autoimmune diseases in healthy subjects persistently positive for antiphospholipid antibodies: long-term follow-up study
16. PO.7.148 Patients with systemic lupus erythematosus and their experience with vaccination against COVID-19: a descriptive and explanatory study
17. Patients with systemic lupus erythematosus and their experience with vaccination against COVID-19: a descriptive and explanatory study
18. AB0455 DRUGS, AUTOANTIBODIES AND GENES CONTRIBUTE TO THE DEVELOPMENT OF CHRONIC DAMAGE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
19. AB0118 PORPHYROMONAS GINGIVALIS AMOUNT IN THE TONGUE BIOFILM IS ASSOCIATED WITH EROSIVE ARTHRITIS IN SYSTEMIC LUPUS ERYTHEMATOSUS
20. POS1058 BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN PSORIATIC ARTHRITIS: PREDICTORS OF TREATMENT SURVIVAL IN A REAL-LIFE SETTING
21. POS0553 NEW BIOMARKERS IN RHEUMATOID ARTHRITIS: ROLE OF HOMOCYSTEINYLATED ANTI-ALPHA1 ANTITRYPSIN ANTIBODIES
22. AB0119 ROLE OF COSTIMULATORY MOLECULES IN SYSTEMIC LUPUS ERYTHEMATOSUS: FOCUS ON CD137
23. POS0410 THE ROLE OF IL-6 IN ENDOTHELIAL DYSFUNCTION: RHEUMATOID ARTHRITIS AND COVID-19, TWO PATHOGENIC MODELS IN COMPARISON
24. AB0436 EFFECTIVENESS OF BELIMUMAB IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: A REAL-LIFE ANALYSIS
25. Fever in systemic lupus erythematosus: associated clinical features and genetic factors
26. POS0685 MYCOPHENOLATE MOFETIL IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: FIVE-YEARS DRUG SURVIVAL IN RENAL AND NON-RENAL INVOLVEMENT
27. POS0783 LUPUS NEPHRITIS: HISTOLOGICAL FEATURES AND LONG TERM OUTCOMES IN A LARGE SINGLE-CENTRE COHORT
28. AB0087 AUTOANTIBODIES DIRECTED AGAINST HOMOCYSTEINYLATED ALPHA 1 ANTITRYPSIN AS A POTENTIAL NEW BIOMARKER FOR ARTHRITIS IN PATIENTS AFFECTED BY SYSTEMIC LUPUS ERYTHEMATOSUS
29. POS1240 HYDROXYCHLOROQUINE CARDIOTOXICITY: A CASE-CONTROL STUDY COMPARING PATIENTS WITH COVID19 AND PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
30. Hydroxychloroquine cardiotoxicity: a case-control study comparing patients with COVID-19 and patients with systemic lupus erythematosus
31. OP0204 LUPUS COMPREHENSIVE DISEASE CONTROL IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS: APPLICATION OF A NEW INDEX
32. THU0227 CAFFEINE INTAKE MODULATES DISEASE ACTIVITY AND CYTOKINES LEVELS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS
33. FRI0159 EROSIVE ARTHRITIS IN SYSTEMIC LUPUS ERYTHEMATOSUS: APPLICATION OF CLUSTER ANALYSIS
34. THU0627-HPR JOINT INVOLVEMENT SIGNIFICANTLY INFLUENCES QUALITY OF LIFE OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS
35. Usefulness of composite indices in the assessment of joint involvement in systemic lupus erythematosus patients: correlation with ultrasonographic score
36. S5A:6 Anti-carbamylated proteins antibodies in sle patients with joint involvement: a possible new biomarker for erosive damage
37. DETECTION OF MACROPHAGE MIGRATION INHIBITORY FACTOR IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS COMPLAINING PAINFUL DISTURBANCES: A SINGLE CENTER STUDY.
38. CAN METHOTREXATE INFLUENCE SEXUAL DYSFUNCTION IN MALE PATIENTS: ANALYSIS OF THE IIEF5 QUESTIONNAIRE AND HORMONAL STATUS.
39. Anti-carbamylated protein antibodies in systemic lupus erythematosus patients with articular involvement
40. SAT0281 Joint activity indices correlates with ultrasonographic score in sle patients with musculo-skeletal involvement
41. THU0696 Anti-carbamylated proteins antibodies in sle patients with joint involvement: a possible new biomarker for erosive damage
42. Anti-carbamylated protein antibodies in systemic lupus erythematosus patients with articular involvement.
43. CROSS-SECTIONAL ASSESSMENT OF THE QUALITY OF LIFE IN SLE PATIENTS: ROLE OF DISEASE ACTIVITY, CHRONIC DAMAGE, FIBROMYALGIA SYNDROME AND MOOD DISORDERS.
44. The demand for Short-Term, safe assets and financial stability: Some evidence and implications for central bank policies
45. Belimumab is Able to Induce a Significant Improvement of Joint Activity Status in Patients Diagnosed with Systemic Lupus Erythematosus: Results From a 12-Month Longitudinal Study
46. Belimumab 10 years later: how drug positioning has changed.
47. Analysis of synovitis patterns in early RA supports the importance of joint-specific factors.
48. Clinical, histologic, and immunologic signatures of Small Fiber Neuropathy in Systemic Lupus Erythematosus.
49. Inclusion of fibrinoid necrosis increases the accuracy of synovial tissue assessment in predicting response to methotrexate: analysis of the UCLouvain Brussels ERA Cohort.
50. Application of SLE-DAS to assess subcutaneous belimumab efficacy in a cohort of systemic lupus erythematosus patients.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.